MUSCARINIC ANTAGONISTS
\mˌʌskɐɹˈɪnɪk antˈaɡənˌɪsts], \mˌʌskɐɹˈɪnɪk antˈaɡənˌɪsts], \m_ˌʌ_s_k_ɐ_ɹ_ˈɪ_n_ɪ_k a_n_t_ˈa_ɡ_ə_n_ˌɪ_s_t_s]\
Sort: Oldest first
-
Drugs that bind to but do not activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC), thereby blocking the actions of endogenous acetycholine or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antagonists that discriminate among the various muscarinic receptor subtypes and might allow better control of peripheral and central actions are under development.
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.